Open menu

Complete Diabetes Medications Table

2021 To quickly search this medication table hold Ctrl+f (windows) or Cmd+f (mac) and type your search term; hit enter. 

Related Links and Key

Diabetes Medication Classes

For quick access, click the medication class:

 

Alpha-Glucosidase Inhibitor

Generic name
Brand names (*coverage) Cost/Month
 Available Strengths
(max daily dose)
Usual Dosing  Health Canada Indications
 Acarbose
Glucobay® (B) $24-$33
 50 or 100 mg
(100 mg tid)
Three times daily
(before meals)

Monotherapy or in combination with metformin, sulfonylurea or insulin



Biguanide (Metformin)

Generic name
Brand names (*coverage) Cost/Month
 Available Strengths
(max daily dose)
Usual Dosing  Health Canada Indications
 Metformin
Glucophage® (B) $4
 500 mg, 850 mg
​(max 2000-2500 mg/day) 
 
2-3 times daily 

Monotherapy or in combination with other antihyperglycemic agents

 Metformin extended release
Glumetza® (NB) $18-$74

500 mg, 1000 mg 
(max 2000 mg/day)
  Once daily   Monotherapy or in combination with other antihyperglycemic agents

 

DPP-4 Inhibitors

Generic name
Brand names (*coverage) Cost/Month
 Available Strengths
(max daily dose)
Usual Dosing  Health Canada Indications
Alogliptin
Nesina® (NB) $66
  6.25 mg, 12.5 mg, 25 mg
(max 25 mg/day)
 Once daily
  • Monotherapy or in combination with metformin, sulfonylurea, pioglitazone or insulin.
  • Use of DPP-4 inhibitors with SGLT-2 inhibitors may not be outlined in the product monograph(s), but is an acceptable combination according to research.
Linagliptin
Trajenta® (SA) $79
5 mg
(max 5 mg/day)
Once daily

  • Monotherapy or in combination with metformin , sulfonylurea, empagliflozin, basal insulin. 
  • Use of DPP-4 inhibitors with other SGLT-2 inhibitors may not be outlined in the product monograph(s), but is an acceptable combination according to research.
  • Boehringer 6m compassionate supply form for MDs.
Saxagliptin
Onglyza® (SA) $75-$88 
 2.5 mg, 5 mg
(max 5 mg/day)
Once daily

  • In combination with metformin, sulfonylurea or insulin. 
  • Use of DPP-4 inhibitors with SGLT-2 inhibitors may not be outlined in the product monograph(s), but is an acceptable combination according to research.
 Sitagliptin
Januvia® (SA) $92 
25 mg, 50 mg, 100 mg
(max 100 mg/day)
Once daily 

  • Monotherapy or in combination with metformin, sulfonylurea, pioglitazone, dapagliflozin or insulin.
  • Use of DPP-4 inhibitors with SGLT-2 inhibitors may not be outlined in the product monograph(s), but is an acceptable combination according to research.
.

  

GLP-1 Agonists (Incretin Mimetics)

Generic name
Brand names (*coverage) Cost/Month
 Available Strengths
(max daily dose)
Usual Dosing  Health Canada Indications
 Dulaglutide injection
Trulicity® (NB) $203

0.75 mg, 1.5 mg, 3 mg, 4.5 mg
(max 4.5 mg/week)

Once weekly injection 
  • Monotherapy or in combination with metformin, sulfonylurea, SGLT-2 or insulin. Sept 11, 2020 Health Canada approved to reduce the risk of non-fatal stroke in adults with type 2 diabetes with multiple CV risk factors or established CV disease.

Exenatide ER (Extended Release)
Bydureon® (NB) $123
To be discontinued Mar 31, 2022

2 mg
(max 2 mg/week)
Once weekly injection
  • Monotherapy or in combination with metformin, sulfonylurea or basal insulin. 
  • Use of a GLP-1 with an SGLT-2 or bolus insulin may not be outlined in product monographs, but are acceptable combinations in type 2 diabetes according to research. 
 Exenatide
Byetta® (NB) $144
 5 mcg, 10 mcg
(max 20 mcg/day)
Twice daily injection 
  • Add-on to metformin or sulfonylurea or glargine.  
  • Use of a GLP-1 with an SGLT-2 or bolus insulin may not be outlined in product monographs, but are acceptable combinations in type 2 diabetes according to research.
 Liraglutide injection
Victoza® (NB) $91- $272
0.6 mg, 1.2 mg, 1.8 mg
(max 1.8 mg/day)
 Once daily injection 
  • Monotherapy or in combination with metformin, sulfonylurea, SGLT-2  or basal insulin. 
  • Add on combination in those with established CV disease & type 2 diabetes.
  • Use of a GLP-1 with bolus insulin may not be outlined in product monographs, but is an acceptable combination in type 2 diabetes according to research.
Lixisenatide injection
Adlyxine® (SA) $113
10 ug, 20 ug
(max 20 ug/day)
Once daily injection
  • Monotherapy or use with metformin, sulfonylurea, pioglitazone or basal insulin.
  • Use of a GLP-1 with an SGLT-2 or bolus insulin may not be outlined in product monographs, but are acceptable combinations in type 2 diabetes according to research.
Semaglutide injection
Ozempic® (SA) $195 
(NIHB Coverage -Non-insured health benefits for First Nations and Inuit)

 0.25, 0.5 mg, 1 mg, 2 mg
(max 2 mg/week) 

 

Once weekly injection 
  • Monotherapy or in combination with metformin, sulfonylurea or basal insulin.
  • Use of a GLP-1 with an SGLT-2 or bolus insulin may not be outlined in product monographs, but are acceptable combinations in type 2 diabetes according to research.
  • For 1 mg pen about 74 clicks forward is 1 mg; 37 clicks forward is 0.5 mg. 
  • 2 mg/wk is a newer dosing (2023). 
  • For individuals on insulin +/- other antihyperglycemic agents with HgA1c < 8.0%, consider decreasing the insulin dose by 20% at onset of OZEMPIC treatment.
  • As of Jan 2024, the current 1.5 mL pen which delivered 0.25 and 0.5 mg doses, will be replaced with a new 3 mL pen. HOWEVER, the larger pens contain the same number of 0.25/0.5 mg doses. The concentration has been changed (reduced) so that bigger pens can be used to address the shortage of the 1.5 mL pens. 
Semaglutide tablets
Rybelsus® (NB) $219.44
(NIHB Coverage -Non-insured health benefits for First Nations and Inuit)

3mg, 7 mg, 14 mg tablet

Once daily tablet
  • Monotherapy or in combination with other medicinal products for the treatment of diabetes (includes SGLT-2, secretagogues, metformin, insulins). 
  • To be taken on an empty stomach, at least 30 min before eating, with no more than 120 mL water. Review rationale here

Tirzepatide injection
Mounjaro (NB) 

2.5 mg, 5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg,15 mg
Once weekly injection
  • Monotherapy or in combination with other medicinal products for the treatment of diabetes.
  • Currently uses vial + syringe [training video here]. Multi-use pen is coming.
  • Use of a GLP-1 with bolus insulin may not be outlined in product monographs, but is an acceptable combination in type 2 diabetes according to research.

Secretagogues (Sulfonylureas and Meglitinides)

Generic name
Brand names (*coverage) Cost/Month
 Available Strengths
(max daily dose)
Usual Dosing  Health Canada Indications
 Gliclazide
Diamicron® (B) $3 - $11
80 mg
(max 320 mg/day)
 Twice daily

 "Non- ketosis prone, maturity onset or adult type" diabetes
Gliclazide modified release
Diamicron MR® (B) $3 - $14
30 mg, 60 mg  
(max 120 mg/day)
Once daily 

"Non- ketosis prone, maturity onset or adult type" diabetes 
Glimepiride
Amaryl® (NB) $29-67
1 mg, 2 mg, 4 mg 
(max 8 mg/day) 
Once daily 

Monotherapy or with metformin or insulin
Glyburide
Diabeta® (B) $2-$6
2.5 mg, 5 mg 
(max 20 mg/day) 
Twice daily
 
Type 2 Diabetes 
Repaglinide
Gluconorm® (B) $7
0.5 mg, 1 mg, 2 mg 
(max 4 mg/meal; 16 mg/day)
At meals
(optional HS snack) 

Monotherapy or with metformin or rosiglitazone 

 SGLT-2 Inhibitors 

Generic name
Brand names (*coverage) Cost/Month
 Available Strengths
(max daily dose)
Usual Dosing  Health Canada Indications
 Canagliflozin (SGLT 2)
Invokana® (SA) $84
 100 mg, 300 mg
(max 300 mg/day)
Once daily 
  • Monotherapy or in combination with metformin, sulfonylurea, pioglitazone, sitagliptin or insulin
  • Use of an SGLT-2 with a GLP-1 or DPP-4 or bolus insulin may not be outlined in product monographs, but each is an acceptable combination in type 2 diabetes according to research.
  • As add-on combination in patients with established cardiovascular disease and type 2 diabetes to reduce the risk of major adverse cardiovascular events.
  • With type 2 diabetes and diabetic nephropathy to reduce the risk of end-stage kidney disease, doubling of serum creatinine, and cardiovascular (CV) death in adult patients with type 2 diabetes mellitus and diabetic nephropathy with albuminuria (>33.9 mg/mmol). 
  • In patients with type 2 diabetes already initiated on treatment for diabetic nephropathy, the use of INVOKANA® 100 mg can be continued in patients with an eGFR <30 mL/min/1.73 m2. INVOKANA® 100 mg should be discontinued if dialysis is initiated. 
Dapagliflozin (SGLT 2)
Forxiga® (SA) $82
5 mg, 10 mg
(max 10 mg/day)
Once daily 
  • Monotherapy or in combination with metformin, sulfonylurea, sitagliptin or insulin or to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and CV risk factors or established CV disease (with eGFR above 45 to impact glycemia). 
  • Use of an SGLT-2 with a GLP-1 or other DPP-4 or bolus insulin may not be outlined in product monographs, but each is an acceptable combination in type 2 diabetes according to research.
  • As an adjunct to standard treatment of heart failure (with or without diabetes) with reduced ejection fraction (HFrEF) to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure and urgent heart failure visit.
  • To reduce the risk of sustained eGFR decline  end-stage kidney disease, and cardiovascular and renal death in adults with chronic kidney disease (CKD, with or without diabetes). Can start if eGFR > 25. Can continue on the dose below this eGFR but discontinued if dialysis. 
 Empagliflozin (SGLT 2)
Jardiance® (SA) $81
10 mg, 25 mg
(max 25 mg/day)
Once daily  
  • For Diabetes: Indicated as monotherapy or in combination with metformin, sulfonylurea, pioglitazone, linagliptin or insulin or as add-on combination in patients with established cardiovascular disease. May provide additional glycemic control at 25 mg if eGFR ≥30. (Use of an SGLT-2 with a GLP-1 or other DPP-4 may not be outlined in product monographs, but each is an acceptable combination in type 2 diabetes according to research.)
  • For Heart Failure and/or Chronic Kidney Disease (CKD): The recommended dose of JARDIANCE is 10 mg taken once daily with an eGFR as low as 20 mL/min/1.73 m2
  • Boehringer 6m compassionate supply form for MDs.
       

Thiazolidinediones (TZDs)

Generic name
Brand names (*coverage) Cost/Month
 Available Strengths
(max daily dose)
Usual Dosing  Health Canada Indications
 Rosiglitazone
Avandia® (SA) $31 - $69
2 mg, 4 mg, 8 mg 
(max 8 mg/day)
Once daily

In combination with metformin or sulfonylurea. Prior to prescribing AVANDIA, physicians must: Document the eligibility of patients to meet the above criteria; Counsel each patient on the risks and benefits of AVANDIA, including the cardiovascular risks; and Obtain the patient’s written informed consent to take the drug. 
Pioglitazone
Actos® (SA) $10- $21
15 mg, 30 mg, 45 mg
(max 45 mg/day)
Once daily 

Monotherapy or in combination with metformin or sulfonylurea.

 

 Combination Medications

Generic name (class)
Brand names (*coverage) Cost/Month
 Available Strengths
(max daily dose)
Usual Dosing  Health Canada Indications
 Alogliptin (DPP-4) + Metformin
Kazano® (NB) $72
12.5 mg / 500 mg
12.5 mg / 850 mg
12.5 mg / 1000 mg
(max 25 mg + 2000 mg/day)
Twice daily Alone or in combination with pioglitazone or insulin 
Linagliptin (DPP-4) + Metformin
Jentadueto® (SA) $83
2.5 mg + 500 mg
2.5 mg + 850 mg
2.5 mg + 1000 mg
(max 5 mg + 2000 mg/day) 
Twice daily Alone or in combination with sulfonylurea or empagliflozin. 
Boehringer 6m compassionate supply form (MDs).
Sitagliptin (DPP-4) + Metformin
Janumet® (SA) $100
50 mg / 500 mg
50 mg / 850 mg
50 mg / 1000 mg 
(max 100 mg + 2000 mg/day)
Twice daily Alone or in combination with sulfonylurea, pioglitazone or insulin. 
Sitagliptin (DPP-4) + Metformin modified release
Janumet XR® (SA) $50 - $99
50 mg / 500 mg
50 mg / 1000 mg
100 mg / 1000 mg 
(max 100 mg + 2000 mg/day)

Once daily with a meal preferably in the evening 

Alone or in combination with sulfonylurea, pioglitazone or insulin. 
Saxagliptin (DPP-4) + Metformin 
Komboglyze® (SA) $76
2.5 mg + 500 mg
2.5 mg + 850 mg
2.5 mg + 1000 mg
(max 5 mg + 2000 mg/day)  
 Twice daily  Alone or in combination with sulfonylurea or insulin.
Saxagliptin (DPP-4) + Dapagliflozin (SGLT-2) 
QTERN® (NB) $ - cost not available; not yet marketed
5 mg / 5 mg
5 mg / 10 mg 
(max 5 mg / 10 mg/day)
Once daily On metformin and saxagliptin alone or
 already controlled with metformin, saxagliptin and dapagliflozin. Can be used with insulin. 
Canagliflozin (SGLT-2) + Metformin
Invokamet® (NB) $95
50 mg / 500 mg
50 mg / 850 mg
50 mg / 1000 mg 
150 mg / 500 mg
150 mg / 850 mg
150 mg / 1000 mg 
(max 300 mg + 2000 mg/day)
Twice daily  Alone or in combination with sulfonylurea, pioglitazone or insulin.
Canagliflozin (SGLT-2) + Metformin modified release
Invokamet XR® (NB); not yet marketed 
50 mg / 500 mg
50 mg / 1000 mg 
150 mg / 500 mg
           150 mg / 1000 mg             (max 300 mg + 2000 mg/day)
Once daily  Alone or in combination with sulfonylurea, pioglitazone or insulin.
Dapagliflozin (SGLT-2) + Metformin
Xigduo® (SA) $74
5 mg / 850 mg
5 mg / 1000 mg
(max 10 mg + 2000 mg/day)
Twice daily  Alone or in combination with sulfonylurea, sitagliptin or insulin. 
Empagliflozin (SGLT-2) + Metformin
Synjardy® (SA) $83
5 mg / 500 mg
5 mg / 850 mg
5 mg / 1000 mg 
12.5 mg / 500 mg
12.5 mg / 850 mg
12.5 mg / 1000 mg
(max 25 mg + 2000 mg/day)
Twice daily 

 Alone or in combination with sulfonylurea, pioglitazone or insulin (not premix).

Boehringer 6m compassionate supply form (MDs).

Empagliflozin (SGLT-2) + Linagliptin (DPP-4)
Glyxambi® (NB) $142
10 mg / 5 mg
25 mg / 5 mg
(max 25 mg + 5 mg/day) 
Once daily  Metformin 
Insulin degludec + liraglutide (GLP-1)
Xultophy® (NB) $185-309

1 unit of Xultophy contains 1 unit of degludec and 0.04 mg liraglutide (fixed ratio)

Starting dose: 16 units
Maximum dose: 50 units

Once daily injection
  • Type 2 diabetes in combination with metformin, with or without sulfonylurea, when these combined with basal insulin (< 50 units daily) or liraglutide (less than or equal to 1.8 mg daily), do not provide adequate glycemic control.
 Insulin glargine + lixisenatide (GLP-1)
Soliqua®  (NB) $228 at max dose
(NIHB Coverage - Non-insured health benefits
for First Nations and Inuit)

1 unit of SOLIQUA contains 1 unit of insulin glargine and 0.33 mcg lixisenatide (fixed ratio)

Starting dose: 15 units/day or 30 units/day
Maximum dose:  60 units/day
 Once daily injection
  • Type 2 diabetes, on basal insulin (< 60 units daily and > 15 units per day) alone or in combination with metformin OR inadquately controlled on GLP-1 in combination with metformin.
  • Taken before the first meal.
  • Starting Doses: 15 units Soliqua  (if current glargine dose < 30 units); 30 units Soliqua (if current glargine dose 30 to <60 units.)
  • Take oral contraceptives at least 1 hour before or at least 11 hours after the dose of SOLIQUA.
  • Suggested adjustments by fasting glucose of past 3 days:
    > 7.8 mmol/L add 4 units
    > 5.6 to < 7.8 mmol/L add 2 units
    4.4 to 5.6 mmol/L, no change
    < 4.4 mmol/L subtract 2 units

  

Insulins

For quick access, click the type of insulin. Or,  hold Ctrl+f (windows) or Cmd+f (mac) and type your search term; hit enter.

 

 Bolus Insulins

Pharmacodynamic action bolus insulins

Titration of Bolus Insulin: See Diabetes Canada Insulin Titration Regimens and our Insulin Adjustments webpage

 

 

Generic name
Brand names (*coverage) Cost/box

 Pharmacodynamics
Onset/Peak/Duration
Discard after room temp  Dosing Considerations

Aspart 
Novorapid® (B)
vial $30; cartridges $61; Prefilled pens no longer available.. 

Novorapid 

10-20 min / 1-3 hrs / 3-5 hrs

 28 days
  • May inject up to 10 minutes before a meal 
  • 1/2 unit NovoPen Echo available (re-usable)
  • Prefilled pens no longer available. 
Aspart: Faster Insulin Aspart
Fiasp® (NB)
vial $30, cartridges $61, prefills $63 

Fiasp 

5-15 min / 1-3 hrs / 3-5 hrs

 28 days
  • May inject 2 mins before meal and up to 20 mins after starting meal
  • Should not be mixed with other insulins
  • Onset is 5 mins earlier than insulin aspart
  • Time to peak is 11mins faster than insulin aspart
  • Offset of effect occurs 12-14 mins earlier than insuilin aspart
  • 1/2 unit NovoPen Echo available (re-usable)
Aspart 
Trurapi® (B)
cartridges $45;  prefills $45
10-20 min / 1-3 hours / 3-5 hours 28 days
  • Biosimilar of insulin aspart from Sanofi-Aventis 
Aspart 
Kirsty® (B)
prefills $42.72 for a pack of five
(also available as a one pack and a 10 mL vial)
10-20 min / 1-3 hours / 3-5 hours 28 days
  • Biosimilar of insulin aspart from Viatris

Lispro 100 u/mL
Admelog® (NB) 
vial $22.70; cartridges $45; prefills $45
30-45 min/ 1-3 hr / 3-5 hr  28 days
  • Biosimilar of lispro from Sanofi-Aventis 
  • Reusable pen is Star
  • Reusable 1/2 unit pen is Junior Star
  • Disposable pen is Solostar
  • Use in all ages, pregnancy, pumps

Lispro 100 u/mL
Humalog® (B)
vial $29; cartridges $58; prefills $57

Humalog100or200u 

30-45 min / 1-3 hr / 3-5 hrs

28 days 
  • Available in 1/2 unit disposable pens with thebrand name "Humalog Junior KwikPen" 
Lispro 200 u/mL
Humalog® (B)
prefills $107

Same as Lispro 100 u/mL 

30-45 min / 1-3 hr / 3-5 hrs

28 days
  • Reserved for patients using > 20 units per day of rapid insulin.
  • Not to be mixed with other insulins
  • Not to be administered via SC infusion pump (not tested)
  • Pre-filled pen is calibrated to give the dose dialled
Glulisine
Apidra® (B)
vial $28; cartridges $53;  prefills $53

Apidra 

10-15 min / 1-1.5 hrs / 3-5 hrs

 28 days
Regular Insulin
Humulin R® (B)
vial $24; cartridges $47

Refer to "regular insulin" line in the image Pharmacodynamic Action Profiles of Bolus Insulins 

30-60 min / 2-4 hrs / 6-8 hrs 

28 days  
Regular Insulin
 Novolin ge Toronto® (B)
vial $24; cartridges $47

Refer to "regular insulin" line in the image Pharmacodynamic Action Profiles of Bolus Insulins 

30-60 min / 2-4 hrs / 6-8 hrs

One month  
Insulin, human biosynthetic
Entuzity® (NB) 500 u/mL - acts as bolus and basal. See in the Basal Insulin Chart below. 
See in basal chart below 28 days  

  Basal Insulins

Pharmacodynamics long acting insulins

Generic name
Brand names (*coverage) Cost/box

Pharmacodynamics
Onset/Peak/Duration
Discard after room temp  Dosing Considerations
Degludec
Tresiba® (B) 2 concentrations
 100 u/mL: prefills $111
200 u/mL: prefills $133
Also see Combination Medications

Tresiba

1 hr / no peak / 42 hrs

8 weeks 
  • Pre-filled pen is calibrated to give the dose dialled, e,g.  80 units u100 = 80 units u200; the latter is contained in less volume. 
  • U100 pen delivers doses in 1 unit increments up to 80 unit per dose
  • U200 pen delivers doses in 2 unit increments up to 160 unit total dose
  • Missed doses may be taken when remembered if at least 8 hrs between doses.
  • Steady state serum concentration is reached after 3-4 days. 
  • Diabetes Canada titration suggestions: 2 units every 3-4 days or 4 units a week. You may wish to use the  Tresiba titration handout
  • Type 2, adult: If "taking once-daily long or intermediate-acting insulin, start TRESIBA® at the same unit dose. For patients transferring from twice daily long or intermediate-acting insulin, or insulin glargine (300 units/mL), it is recommended that the dose of TRESIBA® is reduced by 20% to lower the risk of hypoglycemia."
  • Type 1: Reduce by 20% if patient has type 1 diabetes or if switching from bid basal
  • Also available as the combination medication  Xultophy® (degludec + liraglutide). See combination medications section

 Conversion FROM degludec TO glargine is not standardized. (Eventually, 10-20% more glargine may be required.)  Consider either:

  • Delaying the switch for 2 days e.g. no basal insulin for 48 hours to avoid overlap (Reference). 

    OR

  • Day 1 of change (24 hr after degludec): Give 50% of basal as glargine (or less if worried about lows)
  • Day 2 of change (48 hr after degludec): Give 75%-100% of basal as glargine depending on readings.
  • If type 1, consider that the glargine dose may be divided between bedtime and morning. (Reference). 
 Detemir 
Levemir® (B)
 cartridges $108; Prefilled pens no longer available. 

  Levemir

1.5 hrs /  no peak / 16-24 hrs

42 days 
(6 weeks)

  • Prefilled pens no longer available.
Insulin, human biosynthetic
(basal and/or bolus)
Entuzity® (NB) 500 u/mL
prefills 2/box $94
prefills 5/box $237
(each pen has 1500 units)

Entuzity15 15 min / 4-8  hrs / 17-24 hrs

28 days 

 

  • Indicated for those requiring over 200 units insulin/day
  • Onset similar to U-100
  • Peak slightly lower than Humulin R U100
  • Time to peak is delayed (vs. Humulin R)
  • Dose 30 minutes before meal
  • Given 2-3 times daily
  • When switching to Entuzity and HbA1c < 8% reduce TDD by 20%
  • Pre-filled pen is calibrated to give the dose dialled
  • Pen delivers 5 unit increments
Insulin, human biosynthetic
Humulin N ® (B)
vial $24; cartridges $47; prefills $47

Humulin N 

1-2 hrs / 5-8 hrs / 14-18 hrs

28 days 
  •  Still available as disposable pen as of July 2023
Insulin, human biosynthetic
Novolin ge NPH® (B)
vial $24; cartridges $48

Refer to NPH line in the image Pharmacodynamic Action Profiles of Long-Acting Insulins 

1-2 hrs / 5-8 hrs / 14-18 hrs

 One month
  •  Not available as disposable pen
Glargine
Lantus® (NB on July 1, 2020)
vial $62; cartridges $93; prefills $93
Also see Combination Medications for Soliqua®

Lantus 

1.5 hrs / no peak / 24 hrs

28 days 
Glargine
Basaglar® (B)
cartridges $69; prefills $69

Basaglar 

1.5 hrs / no peak / 24 hrs

 28 days  Biosimilar of insulin glargine
Glargine
Semglee® (B)
Prefills $63.83 for a pack of 5 
(also available in a 1 pack and 3 pack)
1.5 hrs / no peak / 24 hrs 28 days Biosimilar of insulin glargine from Viatris.
Glargine 300 u/mL
Toujeo® (NB)
1.5 mL (450 unit) prefilled SoloSTAR pens $79 

Toujeo 

up to 6 hrs / no peak / up to 36 hrs

42 days
(6 weeks) 
Glargine 300 u/mL 
Toujeo Doublestar
3 mL (900 unit) prefilled pens
$52.86 per each pen.

Toujeo

up to 6 hrs / no peak / up to 36 hrs

42 days
(6 weeks)
  • The prescribed dose of TOUJEO should always be expressed in units of insulin.
  • See Toujeo dosing handout.
  • Pre-filled pen is calibrated to give the dose dialled
  • Pen dials up to 160 units. Dials in two unit increments.

 

  Mixed Insulins

Generic name
Brand names (*coverage) Cost/Month
Pharmacodynamics
Onset/Peak/Duration
Discard after room temp (days) Dosing Considerations
Lispro insulin (% Humalog)/ lispro protamine 
Humulin® Mix25 (B) 
Cartridges $59, Prefills $58

Humulin® Mix50 (B) 
Cartridges $58, Prefills $57

Per insulins lispro (Humalog) and N   28 days

30% regular insulin (R) / 70% insulin isophane (N), 
Humulin®  30/70 (B)
vial $24, cartridges $47
Per insulins R and N  28 days  

 Regular insulin (%Toronto) / insulin (%NPH)
Novolin® ge 30/70 (B)
vial $24, cartridges $46

Novolin® ge 40/60 (B)
cartridges $46

Novolin® ge 50/50 (B) 
cartridges $46

Per insulins Toronto and NPH   1 month  
30% soluble insulin aspart (rapid)/
 70% insulin aspart protamine crystals (NPH)
NovoMix® 30 (NB)
cartridges $56
Per insulins aspart (Novorapid) and NPH  1 month  

 

Glucagon

Generic name
Brand names (*coverage) Cost/Month
Storage Supporting materials and other considerations
glucagon nasal powder
BAQSIMI™
Over $148 (B)
Store BAQSIMI in the shrink wrapped tube at temperatures up to 30°C (86°F).
glucagon injection
Glugagon Amphastar (B)
$301 per one kit
Prior to reconstitution, Vials of GLUCAGON and prefilled Hyporets of Diluting Solution may be stored at controlled room temperature, 15° to 30°C Still available on the Lilly website:
     

 

 

*Verify Alberta Blue Cross coverage through their database